Role of circulating advanced glycation end products (AGEs) in diabetic nephropathy: Effect of benfotiamine intervention [ 2005 - 2007 ]

Also known as: Role of glycation and benfotiamine in diabetic kidney disease

Research Grant

[Cite as]

Researchers: Prof George Jerums (Principal investigator) ,  Dr Sianna Panagiotopoulos Paul Thornalley Prof Dennis Yue Prof Gregory Fulcher
View all 6 related researchers

Brief description Advanced glycation products (AGEs) are compounds formed by the addition of sugars to amino acids (the building blocks of proteins). The addition of sugars to proteins induces biological changes that have been implicated in the development of diabetic complications, especially diabetic kidney disease. AGEs are a diverse group of compounds and to date the exact role that specific AGEs play in the causation of diabetic kidney disease is still unclear. However, new methods are now available that allow the comprehensive quantification of individual AGE levels in blood. Our study involves the comparison of AGE blood levels, as a group or as specific AGEs with markers of diabetic kidney disease such as albumin (protein) excretion in the urine and the rate that the kidney filters the blood to form urine (glomerular filtration rate). Benfotiamine is a thiamine (vitamin B1) derivative that has been shown to decrease the formation of AGEs and to prevent kidney disease in diabetic animals. The present clinical study will assess whether benfotiamine has similar effects on AGEs and kidney disease in patients with type 2 diabetes. If successful, this study has the potential to provide a new treatment strategy for diabetic kidney disease in humans.

Funding Amount $AUD 465,000.00

Funding Scheme NHMRC Project Grants

Notes Standard Project Grant

Viewed: [[ro.stat.viewed]]